Thus, the assigned control group in the present study was clearly insulin resistant similar to the patients with type 2 diabetes but had not developed similar decrease in beta-cell function (as assessed by HOMA2%B), despite fulfilling the ADA criteria for impaired fasting glucose. The gene discussed is INS; the disease is type 2 diabetes mellitus.